Advertisement

Topics

Latest Pricing NewsRSS

06:26 EST 20th February 2017 | BioPortfolio

STAT Plus: Q&A: Time to pull back the veil on pharmacy benefits middlemen

Recent debates about drug pricing have tended to focus on manufacturers and patients, but US Representative Doug Collins is looking at the middlemen.

Telit Communications Plc's (TCM) Buy Rating Reiterated at Canaccord Genuity

's stock had its "buy" rating reaffirmed by Canaccord Genuity in a research note issued on Wednesday. They presently have a GBX 325 price target on the stock.

GlaxoSmithKline plc's (GSK) "Buy" Rating Reiterated at Beaufort Securities

's stock had its "buy" rating reaffirmed by analysts at Beaufort Securities in a research note issued on Thursday, StockTargetPrices.com reports. They currently have a GBX 1,750 target price on the stock.

AC Group to Exhibit the 7 Stages of Value-Based Reimbursement at HIMSS 2017

  MONTGOMERY, Texas, Feb. 19, 2017 /PRNewswire/ -- AC Group Inc., a leading company, specializing in the evaluation, selection, and ranking of vendors in the PMS/EHR healthcare marketplace, will exhibit the 7 Stages of VBR technologies and implementational system requirements to succeed in this ecosystem at HIMSS'17. AC Group gathered together information obtained from over 200 ...

O'Connor fund owns 9.5% of Protalix Biotherapeutics

Protalix's share price has shot up 300% after plunging following a debt settlement in December.

Regeneron Pharmaceuticals, Inc. (REGN) Earns Outperform Rating from Sanford C. Bernstein

's stock had its "outperform" rating reissued by research analysts at Sanford C. Bernstein in a research note issued on Thursday. They presently have a $410.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $420.00.

Alkermes PLC (ALKS) Receives "Neutral" Rating from Cantor Fitzgerald

's stock had its "neutral" rating restated by analysts at Cantor Fitzgerald in a report released on Thursday. They presently have a $51.00 target price on the stock.

The Global SelfMonitoring of Blood Glucose Market to 2025 Prices from USD $2500

The Global SelfMonitoring of Blood Glucose Market to 2025' is GMR Data's latest pharma report, covering the pharmaceutical, commercial and strategic developments in the global SelfMonitoring of Blood Glucose SMBG market. The report highlights key companies, geographies and products that we believe will deliver strong growth across the next decade. SMBG is now globally recognised as an integral par...

Big Pharma really, really doesn't want you to know the true value of its drugs

Kaleo Pharma's Evzio naloxone injector has climbed 600% in price over the last few years, lawmakers say. The company says that's not really a problem.

LVADs may not be cost-effective in Medicare beneficiaries

Medicare beneficiaries with heart failure who were implanted with left ventricular assist devices (LVADs) had a significantly increase in lifetime costs compared with those treated with medical management, according to a cost-effectiveness model.

FDAnews Announces — How to Integrate FDA Device Approval and Reimbursement Webinar, Feb. 22, 2017

Join Steve Terman — Principal Attorney, Olson Frank Weeda Terman Matz — and Gordon Schatz — President, Schatz Reimbursement Strategies — on Feb. 22 when they’ll explain how to strategically blend reimbursement with FDA regulatory issues and identify the need for outcomes data, comparative evidence, professional society guidelines and how to meet Medicare and managed care reimbursement st...

Aetna Shares Bounce Back After Close

Click to view a price quote on AET. Click to research the Health Services industry.

At the Intersection of Health Transformation, ISTS Exhibits at HIMSS17

Look for International Scholarship and Tuition Services, Inc. on the HIMSS17 exhibit floor in Orlando Nashville, TN (PRWEB) February 17, 2017 For the first time, International Scholarship and Tuition Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for the 2017 HIMSS Conference & Exhibition at the Orange County Convention Center in Orlando, Fla....

VERTESS Predicts TrumpCare Means "Yuge" Spending on Healthcare IT

TUCSON, Ariz., Feb. 17, 2017 /PRNewswire/ -- Every sector of the healthcare industry is struggling to figure out what TrumpCare will mean to their businesses. Some will do better under TrumpCare, but most will do worse.  There is one sector, however, which is guaranteed to grow like gangbusters under a Trump administration: Healthcare IT. Here's why: First, there will be a sharp uptick in...

Insider Selling: Cardinal Health, Inc. (CAH) Chairman Sells $16,835,676.62 in Stock

Cardinal Health, Inc. Chairman George S. Barrett sold 217,994 shares of the company's stock in a transaction that occurred on Friday, February 10th. The stock was sold at an average price of $77.23, for a total transaction of $16,835,676.62.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Click to view a price quote on CLVS. Click to research the Drugs industry.

Your Burning Biotech Questions Answered

Click to view a price quote on TSRO. Click to research the Drugs industry.

Teva Pharmaceutical Industries Limited's (TEVA) Hold Rating...

Several other research firms have also commented on TEVA. Mizuho lowered shares of Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating and lowered their price objective for the company from $64.00 to $45.00 in a research report on Monday, October 24th.

United Healthcare Whistleblower Suit Provides 'Interesting' Investment Opportunity

Click to view a price quote on UNH. Click to research the Health Services industry.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Click to view a price quote on SAGE.

Novo Nordisk becomes second pharma company to cap price hikes

Danish pharmaceutical company Novo Nordisk has pledged to limit the price rises of its drugs to single digit increases each year, following the commitment made by Allergan in September 2016.

Biomarkers Market Worth 53.34 Billion USD by 2021

PUNE, India, February 17, 2017 /PRNewswire/ -- According to a new market research report "Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021" published by MarketsandMarkets, the market is proj...

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Click to view a price quote on CELG. Click to research the Drugs industry.

AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial

Click to view a price quote on AZN. Click to research the Drugs industry.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Click to view a price quote on XBI. Click to research the Financial Services industry.

Quick Search
Advertisement
 

review and buy Pricing market research data and corporate reports here